PASITHEA THERAPEUTICS CORP. Selling, General and Administrative Expense
PASITHEA THERAPEUTICS CORP. (KTTA) reported Selling, General and Administrative Expense of $7.05 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2025-03-24
- PASITHEA THERAPEUTICS CORP. selling, general and administrative expense for the quarter ending 2024-03-31 was $2.29M, a 8.29% increase year-over-year.
- PASITHEA THERAPEUTICS CORP. selling, general and administrative expense for the quarter ending 2023-12-31 was $1.80M, a 32.34% decline year-over-year.
- PASITHEA THERAPEUTICS CORP. selling, general and administrative expense for the quarter ending 2023-09-30 was $2.16M, a 16.00% decline year-over-year.
- PASITHEA THERAPEUTICS CORP. selling, general and administrative expense for the quarter ending 2023-06-30 was $1.80M, a 31.06% decline year-over-year.
- PASITHEA THERAPEUTICS CORP. selling, general and administrative expense for fiscal 2024 was $7.05M, a 10.50% decline from fiscal 2023.
- PASITHEA THERAPEUTICS CORP. selling, general and administrative expense for fiscal 2023 was $7.88M, a 20.61% decline from fiscal 2022.
- PASITHEA THERAPEUTICS CORP. selling, general and administrative expense for fiscal 2022 was $9.92M, a 120.27% increase from fiscal 2021.
- PASITHEA THERAPEUTICS CORP. selling, general and administrative expense for fiscal 2021 was $4.51M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 5 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 8 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 9 month as first filed | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | $7.05M 10-K · filed 2025-03-24 | |||||||||
| 2024-03-31 | $2.29M 10-Q · filed 2024-05-14 | $4.09M derived: sum of 2 quarters · filed 2025-03-24 | $6.25M derived: sum of 3 quarters · filed 2025-03-24 | $8.05M derived: sum of 4 quarters · filed 2025-03-24 | ||||||
| 2023-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $3.96M derived: sum of 2 quarters · filed 2025-03-24 | $5.76M derived: sum of 3 quarters · filed 2025-03-24 | $7.88M 10-K · filed 2025-03-24 | ||||||
| 2023-09-30 | $2.16M 10-Q · filed 2023-11-13 | $3.97M derived: sum of 2 quarters · filed 2023-11-13 | $6.08M 10-Q · filed 2023-11-13 | $8.74M derived: sum of 4 quarters · filed 2024-05-14 | ||||||
| 2023-06-30 | $1.80M 10-Q · filed 2023-08-11 | $3.92M 10-Q · filed 2023-08-11 | $6.57M derived: sum of 3 quarters · filed 2024-05-14 | $9.15M derived: sum of 4 quarters · filed 2024-05-14 | ||||||
| 2023-03-31 | $2.12M 10-Q · filed 2024-05-14 | $4.77M derived: sum of 2 quarters · filed 2024-05-14 | $7.35M derived: sum of 3 quarters · filed 2024-05-14 | $9.96M derived: sum of 4 quarters · filed 2024-05-14 | ||||||
| 2022-12-31 | $2.66M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $5.23M derived: sum of 2 quarters · filed 2024-03-29 | $7.84M derived: sum of 3 quarters · filed 2024-03-29 | $9.92M 10-K · filed 2024-03-29 | $12.52M 10-K · filed 2023-03-30 | |||||
| 2022-09-30 | $2.58M 10-Q · filed 2023-11-13 | $3.22M 10-Q · filed 2022-11-14 | $5.19M derived: sum of 2 quarters · filed 2023-11-13 | $7.27M 10-Q · filed 2023-11-13 | $8.59M 10-Q · filed 2022-11-14 | $9.22M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | $2.61M 10-Q · filed 2023-08-11 | $3.08M 10-Q · filed 2022-08-15 | $4.69M 10-Q · filed 2023-08-11 | $5.48M 10-Q · filed 2022-08-15 | $6.64M derived: sum of 3 quarters · filed 2023-08-11 | $7.92M derived: sum of 4 quarters · filed 2023-08-11 | ||||
| 2022-03-31 | $2.08M 10-Q · filed 2023-05-12 | $2.41M 10-Q · filed 2022-05-16 | $4.03M derived: sum of 2 quarters · filed 2023-05-12 | $5.31M derived: sum of 3 quarters · filed 2023-05-12 | $6.03M derived: sum of 4 quarters · filed 2023-05-12 | |||||
| 2021-12-31 | $1.95M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $3.23M derived: sum of 2 quarters · filed 2023-03-30 | $3.96M derived: sum of 3 quarters · filed 2023-03-30 | $4.51M 10-K · filed 2023-03-30 | ||||||
| 2021-09-30 | $1.27M 10-Q · filed 2022-11-14 | $2.00M derived: sum of 2 quarters · filed 2022-11-14 | $2.55M 10-Q · filed 2022-11-14 | |||||||
| 2021-06-30 | $727.95K 10-Q · filed 2022-08-15 | $1.28M 10-Q · filed 2022-08-15 | ||||||||
| 2021-03-31 | $549.61K 10-Q · filed 2022-05-16 | |||||||||
| 2020-12-31 | $40.98K 10-K · filed 2022-03-30 | |||||||||
| 2020-09-30 | $13.97K 10-Q · filed 2021-11-18 | $13.97K 10-Q · filed 2021-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Rocket One Inc. (RKTO) | United States | $0.019B |